Azura Crencia
Clinical trials in mesodermal stem cell therapy encounter hurdles such as establishing standardized protocols, ensuring patient safety, and demonstrating long-term efficacy. Additionally, the regulatory environment is fraught with difficulties, including navigating evolving guidelines, securing approval for novel therapies, and addressing ethical concerns. These factors collectively impact the pace at which promising therapies can be validated and made available to patients. Mesodermal Stem Cell (MSC) therapy holds promise for treating various diseases due to their immune modulatory and regenerative properties. However, its clinical translation faces significant regulatory challenges. This abstract explores the current landscape of clinical trials involving MSC therapy, highlighting regulatory hurdles such as standardization of protocols, safety concerns and ethical considerations.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 